Electric field therapy before lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a device that sends low-energy electrical fields (called Tumor Treating Fields) to the lung tumor before surgery. The goal is to see if it can help shrink the tumor and improve surgical outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC) that is stage I, II, or IIIA and can be removed with surgery.
- You are able to take care of yourself (fully active or up and about more than half the day, but may need some help).
- You have not had any previous treatment for this lung cancer.
- You do not have a pacemaker, defibrillator, or other implanted electronic device.
- You are 22 years of age or older.
- You agree to use effective birth control during the study and for 30 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This pilot study tests a device-based therapy (“Tumor Treating Fields,” TTFields) in people with non-small cell lung cancer (NSCLC) who have an EGFR mutation. The study aims to understand how this treatment affects outcomes and whether it can be done safely.
This trial tests a new treatment called pulsed electric field therapy for people with advanced lung cancer (stage III or IV) that has not responded to first-line immunotherapy. It uses targeted electrical pulses to destroy tumor cells, and may be an option for those who still have other measurable tumors.
This trial tests a combination of targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib) given before surgery for people with a certain type of lung cancer that has not spread too far. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new treatment that uses short electrical pulses (pulsed electric field ablation) to destroy small lung tumors. It may be an option for people with limited, early-stage non-small cell lung cancer who can tolerate a minimally invasive procedure.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.